-
公开(公告)号：US09845291B2
公开(公告)日：2017-12-19
申请号：US14972333
申请日：2015-12-17
Applicant: Genentech, Inc.
Inventor： Jun Liang , Daniel Fred Ortwine , Xiaojing Wang , Steven P. Govek , Mehmet Kahraman , Johnny Y. Nagasawa , Nicholas D. Smith , Simon Charles Goodacre , Nicholas Charles Ray
IPC: A61K31/397 , C07D205/04 , C07D403/12 , A61K31/404 , A61K45/06 , C07D207/04 , A61K31/40 , C07D409/12 , A61K31/4025 , C07D413/12 , A61K31/422 , C07D417/12 , A61K31/427 , C07D401/14 , A61K31/4439 , C07D411/12
CPC classification number: C07D205/04 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/416 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/5415 , A61K45/06 , C07D207/04 , C07D207/08 , C07D401/14 , C07D403/02 , C07D403/12 , C07D403/14 , C07D409/02 , C07D409/12 , C07D411/02 , C07D411/12 , C07D413/02 , C07D413/12 , C07D417/02 , C07D417/12 , C07D417/14 , C07D493/04 , A61K2300/00
Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US20170320871A1
公开(公告)日：2017-11-09
申请号：US15481757
申请日：2017-04-07
Applicant: Genentech, Inc.
Inventor： Sharada Labadie , Jun Liang , Daniel Fred Ortwine , Maia Vinogradova , Xiaojing Wang , Jason Zbieg , Birong Zhang , Tao Wang
IPC: C07D471/04 , C07D401/14 , A61K31/55 , A61K31/4725 , A61K31/5377 , A61K31/4745 , C07D403/12 , C07D401/12
CPC classification number: C07D471/04 , A61K31/4725 , A61K31/4745 , A61K31/5377 , A61K31/55 , C07D401/12 , C07D401/14 , C07D403/12
Abstract: Described herein are tetrahydroisoquinoline compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituent and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US20170312252A1
公开(公告)日：2017-11-02
申请号：US15482584
申请日：2017-04-07
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Kwong Wah Lai , Jun Liang , Birong Zhang , Sharada Labadie , Daniel Ortwine , Peter Dragovich , James Kiefer , Victor S. Gehling , Jean-Christophe Harmange
IPC: A61K31/41 , A61K31/4025 , C07D207/04 , C07D237/04
CPC classification number: A61K31/41 , A61K31/4025 , C07D207/04 , C07D237/04 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14
Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US20160333011A1
公开(公告)日：2016-11-17
申请号：US15220087
申请日：2016-07-26
Applicant: Genentech, Inc.
Inventor： Bing-Yan Zhu , Michael Siu , Steven R. Magnuson , Richard Pastor , He Haiying , Xiao Yisong , Zheng Jifu , Xu Xing , Zhao Junping , Christopher Hurley , Jun Liang , Wendy Liu , Joseph P. Lyssikatos
IPC: C07D471/04
CPC classification number: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/5377 , C07D487/04
Abstract: A compound of Formula I, enantiomers, diastereomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
-
公开(公告)号：US20160175284A1
公开(公告)日：2016-06-23
申请号：US14972336
申请日：2015-12-17
Applicant: Genentech, Inc.
Inventor： Sharada Labadie , Jun Li , Jun Liang , Daniel Fred Ortwine , Xiaojing Wang , Jason Zbieg , Steven P. Govek , Mehmet Kahraman , Johnny Y. Nagasawa , Nicholas D. Smith
IPC: A61K31/4025 , C07D401/12 , A61K31/4184 , C07D401/14 , A61K31/404 , A61K45/06 , A61K31/397
CPC classification number: A61K31/4025 , A61K31/397 , A61K31/404 , A61K31/4184 , A61K45/06 , C07D311/14 , C07D401/12 , C07D401/14
Abstract: Described herein are compounds that are estrogen receptor modulators of Formula I: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Abstract translation: 本文描述的是作为式I的雌激素受体调节剂的化合物：及其立体异构体，互变异构体或其药学上可接受的盐，以及本文所述的取代基和结构特征。 还描述了包括本文所述化合物的药物组合物和药物，以及使用这种雌激素受体调节剂单独使用并与其它化合物联合用于治疗介导或依赖于雌激素受体的疾病或病症的方法。
-
Patent Agency Ranking
56.发明授权Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors 有权羟基化和甲氧基化的嘧啶基环戊烷作为Akt蛋白激酶抑制剂公开(公告)号：US09359340B2
公开(公告)日：2016-06-07
申请号：US14458062
申请日：2014-08-12
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： Ian S. Mitchell , James F. Blake , Rui Xu , Nicholas C. Kallan , Dengming Xiao , Keith Lee Spencer , Josef R. Bencsik , Eli M. Wallace , Stephen T. Schlachter , Anna L. Leivers , Jun Liang , Brian Safina , Birong Zhang , Christine Chabot , Steven Do
IPC: C07D239/70 , C07D403/04 , C07D413/12 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D407/12 , A61P29/00 , A61P35/00 , A61P9/00 , A61P25/28 , A61P15/00 , A61P17/00 , A61K31/517 , A61K31/496
CPC classification number: A61K31/517 , C07D239/70 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12
Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Abstract translation: 本发明提供了包含分解的对映异构体，分解的非对映异构体，溶剂合物和其药学上可接受的盐的化合物，其包含式I：还提供了使用本发明化合物作为AKT蛋白激酶抑制剂和用于治疗过度增殖性疾病 癌症。
-
公开(公告)号：US20160152601A9
公开(公告)日：2016-06-02
申请号：US14086717
申请日：2013-11-21
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： Josef Bencsik , James F. Blake , James M. Graham , Martin F. Hentemann , Nicholas C. Kallan , Ian S. Mitchell , Stephen T. Schlachter , Keith L. Spencer , Dengming Xiao , Rui Xu , Mike Welch , Jun Liang , Brian S. Safina
IPC: C07D403/12 , C07D403/14 , C07D409/14 , C07D413/12 , C07D401/12 , C07D405/14
CPC classification number: C07D403/12 , C07D401/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/12
Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
-
58.发明申请公开(公告)号：US20160152574A9
公开(公告)日：2016-06-02
申请号：US14457582
申请日：2014-08-12
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： Josef R. Bencsik , James F. Blake , Nicholas C. Kallan , Ian S. Mitchell , Keith Lee Spencer , Dengming Xiao , Rui Xu , Christine Chabot , Steven Do , Jun Liang , Brian Safina , Birong Zhang
IPC: C07D239/70
CPC classification number: C07D239/70
Abstract: The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer.
Abstract translation: 本发明提供包含式I的化合物，包括其药学上可接受的盐：还提供使用本发明化合物作为AKT蛋白激酶抑制剂和治疗过度增殖性疾病如癌症的方法。
-
59.发明申请HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS 有权羟基和甲氧基吡咯烷酮作为AKT蛋白激酶抑制剂公开(公告)号：US20140349997A1
公开(公告)日：2014-11-27
申请号：US14458062
申请日：2014-08-12
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： Ian S. Mitchell , James F. Blake , Rui Xu , Nicholas C. Kallan , Dengming Xiao , Keith Lee Spencer , Josef R. Bencsik , Eli M. Wallace , Stephen T. Schlacter , Anna L. Banka , Jun Liang , Brian Safina , Birong Zhang , Christine Chabot , Steven Do
IPC: C07D413/12 , C07D401/12 , C07D409/14 , C07D407/12 , C07D409/12 , C07D239/70 , C07D403/12
CPC classification number: A61K31/517 , C07D239/70 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12
Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Abstract translation: 本发明提供了包含分解的对映异构体，分解的非对映异构体，溶剂合物和其药学上可接受的盐的化合物，其包含式I：还提供了使用本发明化合物作为AKT蛋白激酶抑制剂和用于治疗过度增殖性疾病 癌症。
-
公开(公告)号：US12297210B2
公开(公告)日：2025-05-13
申请号：US17156384
申请日：2021-01-22
Applicant: Genentech, Inc.
Inventor： Terry Kellar , Jun Liang , Sushant Malhotra , Rohan V. Mendonca , Michael Siu , Craig Stivala , John C. Tellis , BinQing Wei , Bryan K. Chan , Lewis J. Gazzard , Timothy Heffron , Graham Jones , Michael Lainchbury , Andrew Madin , Eileen Mary Seward , Matthew W. Cartwright , Emanuela Gancia , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu
IPC: C07D519/00 , A61P37/04 , C07D471/04
Abstract: Naphthyridine compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
-
-
-
-
-
-
-
-
Search Results
79
records
(took 0.061 seconds)
